Allergan plc, a leading global pharmaceutical company, and Medicines360, a nonprofit global women's health pharmaceutical company, announced the launch of the new Liletta (levonorgestrel-releasing ...
SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE: AGN), a ...
Allergan and Medicines360 announced that the Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Liletta (levonorgestrel-releasing intrauterine ...
Allergan plc AGN and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed ...
Allergan plc, a leading global pharmaceutical company, and Medicines360, a nonprofit global women's health pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted ...
The FDA's approval of the supplemental New Drug Application (sNDA) was based on efficacy and safety data from the ongoing Phase 3 ACCESS IUS trial. Allergan and Medicines360 announced that the Food ...
Clinician holding an IUD device The expanded approval was supposed by safety and efficacy data from the Phase 3 ACCESS IUS trial (N=1751) in women receiving Liletta. In the trial, Liletta demonstrated ...
Actavis and Medicines360 announced today that the FDA has granted approval to intrauterine device, Liletta, for the prevention of pregnancy for up to 3 years. “The FDA’s approval of Liletta marks an ...
SAN FRANCISCO, Nov. 14, 2022 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback